Cipher Pharmaceuticals 過去の業績
過去 基準チェック /66
Cipher Pharmaceuticalsは、平均年間19.2%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間23.4% 20.9%収益成長率で 成長しています。 Cipher Pharmaceuticalsの自己資本利益率は23.3%であり、純利益率は60.6%です。
主要情報
19.21%
収益成長率
19.68%
EPS成長率
| Pharmaceuticals 業界の成長 | 23.06% |
| 収益成長率 | 20.88% |
| 株主資本利益率 | 23.25% |
| ネット・マージン | 60.60% |
| 前回の決算情報 | 31 Mar 2026 |
最近の業績更新
Recent updates
ナラティブの更新 • Jun 05
CPH: Fair Outlook Will Balance Buybacks With Expansion And Acquisition Execution
Narrative Update: Cipher Pharmaceuticals The updated analyst price target for Cipher Pharmaceuticals has shifted to CA$17.00 from CA$18.60, reflecting analysts' latest assumptions on discount rate, revenue growth, profit margins, and future P/E, supported by recent Street research that raised targets to CA$21 and CA$22. Analyst Commentary Recent Street research on Cipher Pharmaceuticals has featured a series of price target revisions, with targets cited at CA$20, CA$21, and CA$22, alongside supportive ratings.
ナラティブの更新 • May 22
CPH: Share Repurchases And Higher Conviction Forecasts Will Support Future Upside
Analysts have lifted their price target on Cipher Pharmaceuticals to CA$22 from CA$21, reflecting updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E in recent research. Analyst Commentary Bullish Takeaways Bullish analysts are signaling higher conviction in Cipher Pharmaceuticals' valuation by moving the price target from CA$20 to CA$22 within recent research updates.分析記事 • May 14
Investors Shouldn't Be Too Comfortable With Cipher Pharmaceuticals' (TSE:CPH) Earnings
Cipher Pharmaceuticals Inc. ( TSE:CPH ) announced strong profits, but the stock was stagnant. Our analysis suggests...
ナラティブの更新 • May 08
CPH: Higher Cash Returns And Buybacks Will Support Future Upside
Analysts have lifted their price target on Cipher Pharmaceuticals to CA$21 from CA$20, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E. These changes support a slightly higher fair value estimate.ナラティブの更新 • Apr 23
CPH: Higher Cash Flow Plans And Buybacks Will Support Future Upside
Analysts have nudged their fair value estimate for Cipher Pharmaceuticals to CA$21 from CA$20, tying the CA$1 price target change to updated assumptions around revenue growth, profit margins and a slightly higher discount rate alongside a lower future P/E. Analyst Commentary Recent research points to a modestly higher fair value for Cipher Pharmaceuticals, with bullish analysts lifting their price target to CA$21 from CA$20.ナラティブの更新 • Apr 09
CPH: Fair Outlook Will Weigh Natroba Expansion And Acquisition Execution
Analysts have nudged their price target on Cipher Pharmaceuticals up to CA$21 from CA$20, citing updated assumptions that keep fair value broadly steady while fine tuning expectations around growth, margins, and P/E levels. Analyst Commentary The latest price target move to CA$21 from CA$20 signals only a modest reset in expectations, rather than a major shift in conviction.ナラティブの更新 • Mar 26
CPH: Balanced Outlook Will Weigh New Drug Review And Acquisition Execution
Analysts recently lifted their price target on Cipher Pharmaceuticals to CA$21 from CA$20, reflecting updated assumptions that combine a higher revenue growth outlook with slightly lower profit margin and future P/E expectations. Analyst Commentary The latest price target move to CA$21 suggests that covering analysts are refining their assumptions rather than making a sweeping change in their outlook.ナラティブの更新 • Mar 12
CPH: New Drug Review Will Support Future Upside Potential
Analysts are maintaining their CA$18.60 price target on Cipher Pharmaceuticals. This reflects only small adjustments to their revenue growth and future P/E assumptions, rather than a change in their overall view of the stock.ナラティブの更新 • Feb 26
CPH: New Drug Review And Strong Margins Will Support Further Upside
Analysts kept their CA$18.60 price target on Cipher Pharmaceuticals unchanged, citing only small tweaks to their revenue growth, profit margin and future P/E assumptions that did not materially shift their view of the stock’s value. What's in the News Health Canada accepted Cipher Pharmaceuticals' new drug submission for Natroba (Spinosad) for the treatment of head lice and scabies, moving the product into the formal review process (Key Developments).ナラティブの更新 • Feb 11
CPH: Higher Margins And New Submission Will Support Future Upside
Analysts have trimmed their price target on Cipher Pharmaceuticals to reflect a more muted revenue growth outlook of 4.30% and a slightly higher discount rate of 6.25%, while still acknowledging a stronger projected profit margin of 39.46% and a broadly similar future P/E of 17.63. What's in the News Health Canada accepted Cipher Pharmaceuticals' new drug submission for Natroba (Spinosad), targeting head lice and scabies in the Canadian market (Key Developments).ナラティブの更新 • Jan 26
CPH: Share Repurchases Will Drive Future Earnings Power And Upside Potential
Analysts have modestly adjusted their price target for Cipher Pharmaceuticals to reflect slightly updated assumptions around revenue growth of 10.48%, profit margin of 32.39%, and a future P/E of 17.81x. The overall fair value estimate remains at $18.60.ナラティブの更新 • Jan 11
CPH: Share Repurchases Will Support Stronger Future Earnings Profile
Analysts have trimmed their price target on Cipher Pharmaceuticals by aligning slightly lower revenue growth and profit margin assumptions with a modestly higher future P/E. This keeps fair value around $18.60 and reflects a more measured outlook on the company’s earnings profile.ナラティブの更新 • Dec 27
CPH: Share Repurchases And Rising Margins Will Support Stronger Future Earnings
Cipher Pharmaceuticals' analyst price target has been raised from 14.50 dollars to 18.60 dollars, as analysts cite slightly stronger expected revenue growth, modestly higher profit margins, and a richer future earnings multiple as justification for the upward revision. What's in the News Cipher Pharmaceuticals completed the latest tranche of its share repurchase program between July 1, 2025 and September 30, 2025, buying back 141,700 shares, or 0.56 percent of its float, for CAD 2.18 million (Key Developments) Under the buyback announced on May 1, 2025, the company has now repurchased a total of 371,978 shares, representing 1.46 percent of shares outstanding, for aggregate consideration of CAD 5.12 million (Key Developments) Valuation Changes The consensus analyst price target has risen significantly from 14.50 dollars to 18.60 dollars, reflecting a materially higher fair value assessment.ナラティブの更新 • Dec 12
CPH: Share Buybacks Will Support Earnings And Maintain A Balanced Outlook
Analysts have nudged their price target on Cipher Pharmaceuticals higher, from 14.00 dollars to 14.50 dollars, citing stronger expected revenue growth, improved profit margins, and a more attractive forward earnings multiple despite a slightly higher discount rate. What's in the News Cipher Pharmaceuticals repurchased 141,700 shares between July 1 and September 30, 2025, totaling CAD 2.18 million and representing 0.56% of outstanding shares (company buyback update).分析記事 • Nov 09
Cipher Pharmaceuticals Inc. (TSE:CPH) Analysts Are Pretty Bullish On The Stock After Recent Results
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shareholders are probably feeling a little disappointed, since its shares fell...分析記事 • Oct 10
These 4 Measures Indicate That Cipher Pharmaceuticals (TSE:CPH) Is Using Debt Extensively
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...ナラティブの更新 • Sep 05
Expansion Into Canada Will Shape Global Dermatology Success
Cipher Pharmaceuticals' future P/E has risen sharply, indicating increased valuation relative to earnings, while the net profit margin is stable, resulting in no change to the consensus analyst price target at CA$17.90. What's in the News Cipher Pharmaceuticals is actively seeking accretive acquisitions and in-licensing opportunities, with a strategic focus on complementary U.S.-based assets and companies.分析記事 • Aug 29
Cipher Pharmaceuticals Inc.'s (TSE:CPH) Shares Climb 27% But Its Business Is Yet to Catch Up
The Cipher Pharmaceuticals Inc. ( TSE:CPH ) share price has done very well over the last month, posting an excellent...分析記事 • May 16
We Think That There Are More Issues For Cipher Pharmaceuticals (TSE:CPH) Than Just Sluggish Earnings
Investors weren't pleased with the recent soft earnings report from Cipher Pharmaceuticals Inc. ( TSE:CPH ). Our...分析記事 • May 09
Cipher Pharmaceuticals Inc. (TSE:CPH) Stocks Shoot Up 29% But Its P/E Still Looks Reasonable
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shares have had a really impressive month, gaining 29% after a shaky period...分析記事 • Apr 28
Is Cipher Pharmaceuticals (TSE:CPH) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
新しいナラティブ • Feb 23
Acquisition Of Natroba And Pipeline Products Will Strengthen Future Market Presence
Strategic acquisitions and transitioning to an in-house sales team are aimed at reducing costs and boosting revenue and earnings for Cipher Pharmaceuticals.分析記事 • Dec 13
We Think Cipher Pharmaceuticals (TSE:CPH) Is Taking Some Risk With Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Nov 14
Cipher Pharmaceuticals' (TSE:CPH) Anemic Earnings Might Be Worse Than You Think
Cipher Pharmaceuticals Inc.'s ( TSE:CPH ) earnings announcement last week contained some soft numbers, disappointing...分析記事 • Nov 12
With A 29% Price Drop For Cipher Pharmaceuticals Inc. (TSE:CPH) You'll Still Get What You Pay For
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shareholders won't be pleased to see that the share price has had a very rough...分析記事 • Nov 09
Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shareholders are probably feeling a little disappointed, since its shares fell...分析記事 • Mar 23
There's No Escaping Cipher Pharmaceuticals Inc.'s (TSE:CPH) Muted Earnings Despite A 26% Share Price Rise
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shares have continued their recent momentum with a 26% gain in the last month...分析記事 • Mar 22
Weak Statutory Earnings May Not Tell The Whole Story For Cipher Pharmaceuticals (TSE:CPH)
The market rallied behind Cipher Pharmaceuticals Inc.'s ( TSE:CPH ) stock, leading do a rise in the share price after...収支内訳
収支内訳
Cipher Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 31 Mar 26 | 51 | 31 | 14 | 0 |
| 31 Dec 25 | 50 | 27 | 16 | 0 |
| 30 Sep 25 | 50 | 17 | 17 | 0 |
| 30 Jun 25 | 48 | 12 | 18 | 0 |
| 31 Mar 25 | 40 | 9 | 16 | 0 |
| 31 Dec 24 | 33 | 12 | 12 | 0 |
| 30 Sep 24 | 26 | 16 | 9 | 0 |
| 30 Jun 24 | 22 | 23 | 6 | 0 |
| 31 Mar 24 | 22 | 23 | 6 | 0 |
| 31 Dec 23 | 21 | 20 | 5 | 0 |
| 30 Sep 23 | 21 | 32 | 5 | 0 |
| 30 Jun 23 | 20 | 28 | 5 | 0 |
| 31 Mar 23 | 20 | 27 | 5 | 0 |
| 31 Dec 22 | 21 | 27 | 5 | 0 |
| 30 Sep 22 | 22 | 10 | 5 | 0 |
| 30 Jun 22 | 21 | 8 | 5 | 0 |
| 31 Mar 22 | 22 | 9 | 5 | 0 |
| 31 Dec 21 | 22 | 8 | 5 | 0 |
| 30 Sep 21 | 22 | 5 | 6 | 0 |
| 30 Jun 21 | 23 | 6 | 6 | 0 |
| 31 Mar 21 | 21 | 3 | 6 | 0 |
| 31 Dec 20 | 22 | 4 | 6 | 0 |
| 30 Sep 20 | 21 | 7 | 6 | 0 |
| 30 Jun 20 | 22 | 3 | 5 | 0 |
| 31 Mar 20 | 23 | 4 | 6 | 0 |
| 31 Dec 19 | 22 | 3 | 8 | 0 |
| 30 Sep 19 | 23 | -1 | 11 | 0 |
| 30 Jun 19 | 22 | 2 | 13 | 0 |
| 31 Mar 19 | 23 | 3 | 14 | 1 |
| 31 Dec 18 | 23 | 1 | 14 | 1 |
| 30 Sep 18 | 28 | 6 | 13 | 1 |
| 30 Jun 18 | 34 | 9 | 13 | 0 |
| 31 Mar 18 | 37 | 11 | 13 | 0 |
| 31 Dec 17 | 40 | 11 | 13 | 0 |
| 30 Sep 17 | 34 | 7 | 13 | 0 |
| 30 Jun 17 | 32 | 5 | 13 | 0 |
| 31 Mar 17 | 31 | 1 | 14 | 1 |
| 31 Dec 16 | 30 | 4 | 16 | 1 |
| 30 Sep 16 | 33 | 6 | 23 | 1 |
| 30 Jun 16 | 34 | 2 | 28 | 0 |
| 31 Mar 16 | 34 | 1 | 29 | 0 |
| 31 Dec 15 | 34 | 2 | 29 | 1 |
| 30 Sep 15 | 32 | 3 | 21 | 1 |
| 30 Jun 15 | 30 | 13 | 14 | 1 |
質の高い収益: CPHは 高品質の収益 を持っています。
利益率の向上: CPHの現在の純利益率 (60.6%)は、昨年(23.4%)よりも高くなっています。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: CPHの収益は過去 5 年間で年間19.2%増加しました。
成長の加速: CPHの過去 1 年間の収益成長率 ( 233.9% ) は、5 年間の平均 ( 年間19.2%を上回っています。
収益対業界: CPHの過去 1 年間の収益成長率 ( 233.9% ) はPharmaceuticals業界64.6%を上回りました。
株主資本利益率
高いROE: CPHの 自己資本利益率 ( 23.3% ) は 高い とみなされます。
総資産利益率
使用総資本利益率
過去の好業績企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/06/09 05:41 |
| 終値 | 2026/06/09 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Cipher Pharmaceuticals Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8
| アナリスト | 機関 |
|---|---|
| David Novak | ATB Cormark Historical (Cormark Securities) |
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Prakash Gowd | CIBC Capital Markets |